Te‐Chun Hsia - Concepedia

Author

Te‐Chun Hsia

China Medical University

Also Known As

T. C. Hsia, T. Hsia, T.-C. Hsia, T.C. Hsia, TE-CHUN HSIA, Te-Chun HSIA, Te-Chun Hsia, Te-chun Hsia, Te‐Chun Hsia

162

Publications

9.4K

Citations

H-Index

111

Concepts

All Affiliations

China Medical University China Medical University Hospital Asia University National Chung Hsing University National Yang Ming Chiao Tung University

About

Te‐Chun Hsia is an author at China Medical University specializing in medicine, lung cancer, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	28	48	3.3K
2	Health Sciences	5	5	221
3	Allergy	3	3	82
4	Natural Sciences	2	2	120
5	Public Health	2	2	45

Te‐Chun Hsia

117

Publications

9.3K

Citations

H-Index

Page 1

	Year	Citations
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial Tony Mok, Yi‐Long Wu, Iveta Kudaba, The Lancet	2019	3.2K
Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial James Chih‐Hsin Yang, Jin‐Yuan Shih, Wu‐Chou Su, The Lancet Oncology Advanced Lung DiseaseMedicineLung AdenocarcinomaPathologyLux-lung 2	2012	402
Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy Heng‐Huan Lee, Ying‐Nai Wang, Weiya Xia, Cancer Cell MedicineImmunologyGlycobiologyPharmacotherapyCarbohydrate-protein Interaction	2019	387
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial Yi‐Long Wu, Ying Cheng, Jianying Zhou, The Lancet Respiratory Medicine OncologyMet AmplificationMedicinePathologyPhase 1B/2	2020	249
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations Chao‐Hua Chiu, Cheng‐Ta Yang, Jin‐Yuan Shih, Journal of Thoracic Oncology MedicineReceptor Tyrosine KinaseCancer GrowthPathologyAdvanced Lung Adenocarcinomas	2015	240
Chrysophanol induces necrosis through the production of ROS and alteration of ATP levels in J5 human liver cancer cells Chi‐Cheng Lu, Jai‐Sing Yang, An-Cheng Huang, Molecular Nutrition & Food Research	2010	208
Danthron, an Anthraquinone Derivative, Induces DNA Damage and Caspase Cascades-Mediated Apoptosis in SNU-1 Human Gastric Cancer Cells through Mitochondrial Permeability Transition Pores and Bax-Triggered Pathways Jo‐Hua Chiang, Jai‐Sing Yang, Chia-Yu Ma, Chemical Research in Toxicology	2010	194
INHIBITION OF LUNG CANCER CELL GROWTH BY QUERCETIN GLUCURONIDES VIA G2/M ARREST AND INDUCTION OF APOPTOSIS Jen‐Hung Yang, Te‐Chun Hsia, Hsiu‐Maan Kuo, Drug Metabolism and Disposition	2005	164
Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial James Chih‐Hsin Yang, D. Ross Camidge, Cheng‐Ta Yang, Journal of Thoracic Oncology Pretreated PatientsNovel TherapyMedicinePharmacologyClinical Trials	2020	149
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial Martin Schüler, James Chih‐Hsin Yang, K. Park, Annals of Oncology	2015	131

Page 1